Unique ID issued by UMIN | UMIN000021097 |
---|---|
Receipt number | R000024203 |
Scientific Title | A clinical study for evaluating the effects of lactic acid bacteria FK-23 on controlling intestinal functions (improvement of bowel movement) |
Date of disclosure of the study information | 2016/05/31 |
Last modified on | 2019/02/21 13:04:17 |
A clinical study for evaluating the effects of lactic acid bacteria FK-23 on controlling intestinal functions (improvement of bowel movement)
A clinical study for evaluating the effects of lactic acid bacteria FK-23 on controlling intestinal functions (improvement of bowel movement)
A clinical study for evaluating the effects of lactic acid bacteria FK-23 on controlling intestinal functions (improvement of bowel movement)
A clinical study for evaluating the effects of lactic acid bacteria FK-23 on controlling intestinal functions (improvement of bowel movement)
Japan |
Healthy volunteers
Gastroenterology |
Others
NO
To investigate the effects of 2-week intake of lactic acid bacteria FK-23 on controlling intestinal functions in healthy volunteers with a tendency to be constipated
Safety,Efficacy
Defecation frequency
Population of bifidobacterium to total bacteria, feeling after defecation, smell of feces, defecation days, fecal condition
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
4
Treatment
Food |
Powder food containing FK-23 (0.25 g)
Powder food containing FK-23 (0.075 g)
Powder food containing FK-23 (0.025 g)
Powder food not containing FK-23 (placebo)
20 | years-old | <= |
65 | years-old | >= |
Male and Female
1)Healthy subject within 20-65 years of age, both genders, with constipation tendency (with defecation frequency from 3 to 5 times per week)
2)Subject having a briefing of the content of the present study, fully understanding and agreeing to its objective and being able to personally sign a written informed consent
1)Subject receiving treatment for gastrointestinal diseases
2)Subject having a medical history with organic constipation or irritable bowel syndrome
3)Subject taken medicines for intestinal disorder or laxatives
4)Subject taking medicine, quasi-drugs, food for specified health uses or foods with functional claims having the effects for intestinal functions
5)Subject having serious liver diseases, cardiovascular, respiratory, endocrine or metabolic disorders, or having a medical history with them
6)Subject have a medical history with test food-ralated allergy
7)Female subject who is pregnant or lactating, or intending to become pregnant during the study
8)Subject who took part in another clinical study within 3 months prior to the start of the present study or who is currently taking part in another clinical study
9)Subject deemed unsuitable by the investigator
60
1st name | |
Middle name | |
Last name | Osami Kajimoto |
Osaka City University Graduate School of Medicine
Department of Medical Science on Fatigue
1-4-3 Asahi-machi, Abeno-ku, Osaka
06-6645-6171
kajimoto@med.osaka-cu.ac.jp
1st name | |
Middle name | |
Last name | Tomohiro Sugino |
Soiken Inc.
R&D Division
Senri Life Science Center 13F, 1-4-2, Shinsenri-higashimachi, Toyonaka, Osaka
06-6871-8888
sugino@soiken.com
Soiken Inc.
Nichinichi Pharmaceutical Co., Ltd.
Profit organization
NO
2016 | Year | 05 | Month | 31 | Day |
Unpublished
Completed
2015 | Year | 12 | Month | 19 | Day |
2016 | Year | 02 | Month | 20 | Day |
2016 | Year | 02 | Month | 19 | Day |
2019 | Year | 02 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024203